CN116440069A - Lubrication anesthesia antibacterial eye ointment and preparation method and application thereof - Google Patents
Lubrication anesthesia antibacterial eye ointment and preparation method and application thereof Download PDFInfo
- Publication number
- CN116440069A CN116440069A CN202310702479.2A CN202310702479A CN116440069A CN 116440069 A CN116440069 A CN 116440069A CN 202310702479 A CN202310702479 A CN 202310702479A CN 116440069 A CN116440069 A CN 116440069A
- Authority
- CN
- China
- Prior art keywords
- eye ointment
- lubricating
- eye
- quaternized chitosan
- glycosaminoglycan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003885 eye ointment Substances 0.000 title claims abstract description 71
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 37
- 238000005461 lubrication Methods 0.000 title claims abstract description 15
- 206010002091 Anaesthesia Diseases 0.000 title claims abstract description 13
- 230000037005 anaesthesia Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims abstract description 55
- 230000001050 lubricating effect Effects 0.000 claims abstract description 34
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 33
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- 230000003444 anaesthetic effect Effects 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229960004919 procaine Drugs 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 229960002372 tetracaine Drugs 0.000 claims description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 abstract description 39
- 210000005252 bulbus oculi Anatomy 0.000 abstract description 22
- 239000006071 cream Substances 0.000 abstract description 13
- 238000002834 transmittance Methods 0.000 abstract description 8
- 238000007689 inspection Methods 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 210000004087 cornea Anatomy 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229960003923 gatifloxacin Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000004781 alginic acids Chemical class 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- -1 obucaine Chemical compound 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 201000005675 papillary conjunctivitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a lubrication anesthesia antibacterial eye ointment, and a preparation method and application thereof. Compared with the prior art, the eye ointment has the advantages that the polymer aggregate formed by the glycosaminoglycan and the quaternized chitosan is used as the eye ointment, the viscosity is moderate, the eye ointment is easy to be smeared on eyeballs, and the eye ointment can not be diluted or washed away by ocular secretion in the inspection process, can be stably covered on the eyeballs, and ensures that the cornea is contacted with the ophthalmoscope to not hurt the eyeballs; the polymer aggregate is colorless and transparent, the light transmittance is high, the obtained photo is high in definition, and the accuracy of the inspection result is improved; furthermore, the glycosaminoglycan and the quaternized chitosan have extremely excellent biocompatibility, and meanwhile, the quaternized chitosan has excellent antibacterial property and does not generate drug resistance, so that the lubricating eye cream has local antibacterial and transparent lubricating properties, has minimal irritation to eyeballs, hardly causes adverse reaction, and is suitable for being used in infants.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a lubrication anesthesia antibacterial eye ointment, and a preparation method and application thereof.
Background
The vitreous, retina, choroid and optic nerve are checked by eyeground screening, and the diseases which can be screened include cornea abnormality, congenital cataract, glaucoma, retinopathy of prematurity, eyeground hemorrhage, deformity, infection, infant retinoblastoma and the like. In recent years, with the development of technology and the popularization of fundus screening projects, more and more parents recognize the importance and necessity of fundus screening for infants.
Fundus screening is mainly used for rapid, simple and noninvasive examination of neonatal eyes using wide area retinal imaging systems, but cornea contact ophthalmoscopes require direct contact with the eyeballs during the examination. The following problems are mainly present in the examination of the contacted eyeballs: 1) The instrument stimulates the eyeball and has obvious discomfort to the eye; 2) Bacteria are easily introduced, resulting in ocular infections. Therefore, it is often necessary to apply eye ointment as a lubricant to the eye during the examination.
At present, most of common eye pastes in the market are antibiotic eye pastes, including erythromycin eye paste, ofloxacin eye paste, aureomycin hydrochloride eye paste, gatifloxacin gel eye paste and the like. Among them, most of erythromycin eye ointment, ofloxacin eye ointment and chlortetracycline hydrochloride eye ointment are white to yellow ointments, which have not only no light transmittance but also a viscous shape making it difficult to be smeared on eyeballs. Therefore, these several eye ointments cannot be used as a lubricating eye ointment in fundus screening. The gatifloxacin gel eye ointment is transparent and colorless, wherein the gatifloxacin can play a role in sterilizing as an antibiotic, and is a common lubricating eye ointment in clinic. However, gatifloxacin gel eye ointments have the following disadvantages: 1) The viscosity is low, the liquid is easy to dilute and take away by ocular secretion, and the eyeball can not be covered stably; 2) The light transmittance is low, the definition of the obtained photo is low, and the inspection result is affected; 3) Discomfort of eyes cannot be relieved in the using process; 4) Gatifloxacin is a quinolone antibiotic, has great irritation to the eye ball, long half-life and cartilage development toxicity, and is particularly suitable for infants, especially newborns and premature infants, and can cause more adverse reactions after use, such as: conjunctival irritation, lacrimation, keratitis and papillary conjunctivitis, even bulbar conjunctival edema, conjunctival congestion, dry eyes, lacrimation, ocular irritation, ocular pain, eyelid edema, headache, pinkeye, hypopsia and dysgeusia. Tobramycin eye ointment is also clinically used, has the defect similar to gatifloxacin gel eye ointment, is an aminoglycoside antibiotic, has ototoxicity and renal toxicity, is a forbidden medicine for infants in China, is not popular in the Chinese, and has a possibility of higher ototoxicity for infants carrying the deafness gene. In addition, most of the conventional eye ointments are added with antibiotics for the purpose of antibacterial effect. However, frequent use of antibiotics can lead to resistance.
In addition, in the prior art, the eye ointment almost directly uses a polymer aqueous solution as a carrier, but the polymer aqueous solution is diluted after contacting with an eye secretion, the viscosity is reduced, and the eyeball cannot be covered stably.
Disclosure of Invention
In view of the above, the technical problem to be solved by the present invention is to provide a lubrication anesthetic antibacterial eye ointment with high biocompatibility and antibacterial property, and a preparation method and application thereof.
The invention provides a lubrication anesthesia antibacterial eye ointment, which comprises a high polymer aggregate;
the polymer aggregate is formed by glycosaminoglycan and quaternized chitosan.
Preferably, the number average molecular weight of the quaternized chitosan is 50000-150000; the substitution degree of the quaternized chitosan is 85% -90%.
Preferably, the glycosaminoglycan is selected from hyaluronic acid.
Preferably, the glycosaminoglycan has a number average molecular weight of 50000-100000.
Preferably, the mass ratio of the glycosaminoglycan to the quaternized chitosan is (1-3): (3-1).
Preferably, ophthalmic surface anesthetics are also included; the mass of the ophthalmic surface anesthetic is 0.2% -0.8% of the mass of the lubricating eye ointment.
Preferably, the ophthalmic surface anesthetic is selected from one or more of procaine, tetracaine, obucaine and lidocaine.
The invention also provides a preparation method of the lubrication anesthesia antibacterial eye ointment, which comprises the following steps:
mixing the aqueous solution of glycosaminoglycan and the aqueous solution of quaternized chitosan, and centrifuging to obtain the lubricating anesthetic antibacterial eye ointment.
Preferably, the mass concentration of the glycosaminoglycan in the aqueous solution of the glycosaminoglycan is 1% -5%;
the mass concentration of the quaternized chitosan in the water solution of the quaternized chitosan is 1% -5%.
The invention also provides application of the lubricating anesthetic antibacterial eye ointment as a lubricating eye ointment for fundus screening.
The invention provides a lubrication anesthesia antibacterial eye ointment, which comprises a high polymer aggregate; the polymer aggregate is formed by glycosaminoglycan and quaternized chitosan. Compared with the prior art, the eye ointment has the advantages that the polymer aggregate formed by the glycosaminoglycan and the quaternized chitosan is used as the eye ointment, the viscosity is moderate, the eye ointment is easy to be smeared on eyeballs, and the eye ointment can not be diluted or washed away by ocular secretion in the inspection process, can be stably covered on the eyeballs, and ensures that the cornea is contacted with the ophthalmoscope to not hurt the eyeballs; the polymer aggregate is colorless and transparent, the light transmittance is high, the obtained photo is high in definition, and the accuracy of the inspection result is improved; furthermore, the glycosaminoglycan and the quaternized chitosan in the polymer aggregate have extremely excellent biocompatibility, and the quaternized chitosan has excellent antibacterial property and does not generate drug resistance, so that the lubricating eye cream has local antibacterial and transparent lubricating properties, has minimal stimulation to eyeballs, hardly causes adverse reaction, and is suitable for being used in infants.
Furthermore, the ophthalmic surface anesthetic is added into the lubrication anesthesia antibacterial eye ointment, so that the eye ointment can relieve eye discomfort, has the functions of ocular surface anesthesia, local antibacterial and light transmission lubrication, reduces operation steps, reduces eye discomfort and infection risk caused by overaction, and optimizes the screening technical flow.
Drawings
FIG. 1 is a mass ratio of quaternized chitosan to hyaluronic acid of 1 in example 1 of the present invention: 1, a photograph of the mixture after centrifugation;
FIG. 2 shows that the mass ratio of quaternized chitosan to hyaluronic acid in example 1 of the present invention is 1:1, and obtaining a rheological property test result graph of the coacervate after centrifuging the mixture;
FIG. 3 shows the mass ratio of quaternized chitosan to hyaluronic acid of example 1 of the present invention as 1:1, centrifuging the mixture to obtain an infrared spectrogram of the coacervate;
FIG. 4 is a photograph of QHP-1, QHP-2, QHP-3, QHP-4 and QHP-5 eye pastes obtained in example 1 of the present invention;
FIG. 5 is a fluorescent staining chart and a cell activity bar chart of QHP-1 eye cream obtained in example 1 of the present invention;
FIG. 6 is a bar graph showing the survival rate of plates and bacteria after antibacterial culture of QHP-1 eye cream obtained in example 1 of the present invention;
FIG. 7 is an image of gatifloxacin gel eye ointment, quaternized chitosan/hyaluronic acid coacervate (mass ratio 1:1), QHP-1 eye ointment in example 1 of the present invention;
FIG. 8 shows the quaternized chitosan and alginic acid 1 of comparative example 1:1 to form a photograph of the mixed solution.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The invention provides a lubricating eye ointment, which comprises high molecular aggregate; the polymer aggregate is formed by glycosaminoglycan and quaternized chitosan.
Wherein the number average molecular weight of the quaternized chitosan is 50000-150000, more preferably 80000-120000, still more preferably 100000; the substitution degree of the quaternized chitosan is 85% -90%. The aminated chitosan is polycation, is easy to act with negative charge groups on the surface of bacterial cells, changes the fluidity and permeability of cell membranes, and causes leakage of nutrient components to generate antibacterial effect; and the chitosan molecule is rich in active amino groups, can be adsorbed with pathogenic bacteria cell membranes and flocculate and coagulate the pathogenic bacteria cell membranes, so that the reproductive capacity of the chitosan is inhibited, and pathogenic bacteria metabolism is blocked.
The glycosaminoglycan is preferably hyaluronic acid; the number average molecular weight of the hyaluronic acid is preferably 50000 to 100000, more preferably 60000 to 90000, and still more preferably 80000.
The mass ratio of the glycosaminoglycan to the quaternized chitosan is preferably (1-3): (3-1), more preferably (1-2): (2-1), more preferably (1-1.5): (1.5 to 1), most preferably 1:1, a step of; the viscosity of the polymer aggregate can be regulated by changing the proportion of the glycosaminoglycan to the quaternized chitosan.
The invention takes the polymer aggregate formed by glycosaminoglycan and quaternized chitosan as the eye lubricating ointment, has moderate viscosity, is easy to be smeared on eyeballs, can not be diluted or washed away by ocular secretion in the examination process, can be stably covered on the eyeballs, and ensures that the cornea contacts the ophthalmoscope without damaging the eyeballs; the polymer aggregate is colorless and transparent, the light transmittance is high, the obtained photo is high in definition, and the accuracy of the inspection result is improved; furthermore, the glycosaminoglycan and the quaternized chitosan in the polymer aggregate have extremely excellent biocompatibility, and the quaternized chitosan has excellent antibacterial property and does not generate drug resistance, so that the lubricating eye cream has local antibacterial and transparent lubricating properties, has minimal stimulation to eyeballs, hardly causes adverse reaction, and is suitable for being used in infants.
According to the present invention, the lubricating eye cream preferably further comprises an ophthalmic surface anesthetic; the mass of the ophthalmic surface anesthetic is preferably 0.2% -0.8%, more preferably 0.4% -0.6%, and still more preferably 0.5% of the mass of the lubricating eye ointment; the ophthalmic surface anesthetic includes, but is not limited to, one or more of procaine, tetracaine, obucaine, and lidocaine; these surface anesthetics are non-irritating to the eye and cause little adverse reactions after use. The ophthalmic surface anesthetic is added into the lubricating eye ointment, so that the discomfort of eyes can be relieved, and the eye ointment has the functions of ocular surface anesthesia, local antibacterial and light-transmitting lubrication.
The invention also provides a preparation method of the eye lubricating ointment, which comprises the following steps: mixing the aqueous solution of glycosaminoglycan with the aqueous solution of quaternized chitosan, and centrifuging to obtain the eye ointment.
The sources of all raw materials are not particularly limited, and the raw materials are commercially available; the glycosaminoglycan and the quaternized chitosan are the same as those described above, and are not described herein.
In the present invention, the aqueous solution of glycosaminoglycan is preferably obtained by dissolving glycosaminoglycan in water; the mass concentration of the glycosaminoglycan in the aqueous solution of the glycosaminoglycan is preferably 1% -5%, more preferably 2% -3%, and still more preferably 2%.
The aqueous solution of quaternized chitosan is preferably obtained by dissolving quaternized chitosan in water; the mass concentration of the quaternized chitosan in the aqueous solution of the quaternized chitosan is preferably 1% -5%, more preferably 2% -3%, and even more preferably 2%.
Mixing an aqueous solution of glycosaminoglycan with an aqueous solution of quaternized chitosan, and centrifuging; the mass ratio of the aqueous solution of the glycosaminoglycan to the aqueous solution of the quaternized chitosan is preferably (1-3): (3-1), more preferably (1-2): (2-1), more preferably (1-1.5): (1.5 to 1), most preferably 1:1, a step of; the rotation speed of the centrifugation is preferably 1000-10000 rpm, more preferably 3000-8000 rpm, and still more preferably 5000 rpm; the centrifugation time is preferably 1-10 min, more preferably 3-8 min, and still more preferably 5 min; and (3) centrifuging to obtain polymer aggregate which is not miscible with the supernatant.
According to the invention, after centrifugation, the polymer condensate on the lower layer is preferably mixed with the ophthalmic surface anesthetic and stirred uniformly, thus obtaining the lubricating eye ointment; the types and amounts of the ophthalmic surface anesthetics are the same as described above and are not described in detail herein.
The invention also provides application of the eye ointment as eye ointment for fundus screening.
Further preferably, the above-mentioned lubricating eye cream is used as an infant fundus screening lubricating eye cream.
The eye ointment is used for fundus screening (especially for infant fundus screening), and can be applied to eyeball for lubrication, anesthesia and antibiosis.
The invention also provides application of the eye ointment as an eye operation preparation.
In order to further illustrate the present invention, the following describes in detail a lubricating eye ointment, a preparation method and application thereof provided by the present invention with reference to examples.
The reagents used in the examples below are all commercially available.
Example 1: preparation and application of quaternized chitosan/Hyaluronic acid (Quaternized chitosan/Hyaluronic acid, QH) -procaine (P) (abbreviated as QHP eye ointment)
Quaternized chitosan (number average molecular weight: 100000, 85% -90%) and hyaluronic acid (number average molecular weight: 80000) were dissolved in deionized water, respectively, at concentrations of 2.0. 2.0 wt%. Then two kinds of polymer solutions are mixed according to the ratio of 1:1,1:2,1:3,2:1,3:1, and centrifuging the mixture to obtain a coacervate immiscible with the upper liquid.
FIG. 1 shows that the mass ratio of quaternized chitosan to hyaluronic acid is 1:1, as can be seen from fig. 1, the lower layer material has fluidity and is not miscible with the aqueous solution.
The mass ratio of the quaternized chitosan to the hyaluronic acid is 1:1, and the rheological property of the coacervate obtained after the mixture is centrifuged is tested, and the rheological test result is shown in fig. 2. As can be seen from fig. 2, the storage modulus of the material is less than the loss modulus, and therefore, it can be determined that the material is a coacervate.
The mass ratio of the infrared spectrum to the quaternized chitosan, the hyaluronic acid is 1:1 quaternized chitosan and hyaluronic acid to obtain coacervate, and analyzing to obtain infrared spectrogram shown in figure 3. As can be seen from fig. 3, after the quaternized chitosan and the hyaluronic acid were combined, the characteristic peaks of the amino group and the carboxyl group were shifted, and no new characteristic peak was generated, indicating that the two were combined by physical action.
Subsequently, 0.5% wt% of procaine is added into the polymer coacervate, the mixture is stirred and mixed uniformly, and bubbles in the coacervate are removed by centrifugation or vacuumizing, so that colorless and transparent QHP-1 (mass ratio 1:1), QHP-2 (mass ratio 1:2), QHP-3 (mass ratio 1:3), QHP-4 (mass ratio 2:1) and QHP-5 (mass ratio 3:1) eye pastes are obtained, and photographs of the eye pastes are shown in fig. 4.
The regulation performance: the viscosity and transmittance of the eye ointment were measured by a rheometer (rotation frequency 1 Hz, rotation deformation 1%) and an ultraviolet-visible spectrometer (whether or not the wavelength of the incident light was required) respectively, with the results shown in table 1. Wherein, the polymer ratio is 1:1, the QHP-1 eye ointment has the most suitable viscosity and light transmittance. In addition, compared with gatifloxacin eye ointment (Diyou), the QHP-1 eye ointment has more proper viscosity and better lubrication effect on eyeballs.
TABLE 1 influence of varying the high molecular content on the viscosity and transmittance of eye pastes
Cell biocompatibility of QHP-1 eye-cream: after incubating 3T3 cells with QHP-1 eye ointment for 24 hours, a fluorescence staining pattern and a cell activity histogram were obtained by using fluorescence staining (Calcein/PI cell activity and cytotoxicity detection kit), as shown in FIG. 5. As can be seen from fig. 5, the cells showed good cell viability and exhibited a fusiform shape, with no significant difference from the positive control group (cell culture medium alone). This result shows that the QHPE-1 eye cream has good cell biocompatibility, which has important significance for eye cream which directly contacts the eyeball.
Antibacterial properties of QHP-1 eye cream: after the QHP-1 eye ointment and the escherichia coli suspension are cultivated for 12 hours in a 37 ℃ incubator, the suspension is paved on an agar plate, and cultivation is continued for 12 hours in the 37 ℃ incubator; the untreated bacterial suspension was treated as a positive control group in the same manner; a bar graph of bacterial viability after incubation is shown in FIG. 6. As can be seen from FIG. 6, the bacterial suspension treated with QHP-1 eye ointment showed no colony growth on the agar plate, a sterilization rate of 90%, and a positive control group showed a distinct colony. These results indicate that QHP-1 eye-cream has excellent antibacterial properties.
Imaging experiments of various eye ointments on experimental rabbit eyes: the different eye pastes are smeared on experimental rabbit eyes, then a wide area retina imaging system is used for imaging each group of experimental rabbit eyes, and imaging photos are obtained as shown in fig. 7; the imaging results are analyzed as in table 2.
TABLE 2 Experimental Rabbit eye imaging results and results analysis Using different eye pastes
Comparative example 1
Quaternized chitosan (number average molecular weight: 100000, 85% -90%) and alginic acid (number average molecular weight: 80000) were dissolved in deionized water, respectively, at concentrations of 2.0. 2.0 wt%. Then two kinds of polymer solutions are mixed according to the ratio of 1:1, and centrifuging the mixture to obtain a photograph of the product as shown in fig. 8. From fig. 8, it is clear that the mixture of the quaternized chitosan and alginic acid forms only a mixed solution, and no coacervate is obtained.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (10)
1. A lubrication anesthesia antibacterial eye ointment is characterized by comprising high molecular aggregate;
the polymer aggregate is formed by glycosaminoglycan and quaternized chitosan.
2. The lubricating anesthetic antibacterial eye ointment of claim 1, wherein the quaternized chitosan has a number average molecular weight of 50000-150000; the substitution degree of the quaternized chitosan is 85% -90%.
3. The lubricating anesthetic antibacterial eye ointment of claim 1, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid.
4. The lubricating anesthetic antibacterial eye ointment of claim 1, wherein the glycosaminoglycan has a number average molecular weight of 50000-100000.
5. The lubricating anesthetic antibacterial eye ointment according to claim 1, wherein the mass ratio of the glycosaminoglycan to the quaternized chitosan is (1-3): (3-1).
6. The lubricating anesthetic antibacterial eye ointment of claim 1, further comprising an ophthalmic surface anesthetic; the mass of the ophthalmic surface anesthetic is 0.2% -0.8% of the mass of the lubricating eye ointment.
7. The lubricating anesthetic antibacterial eye ointment of claim 6, wherein the ophthalmic surface anesthetic is selected from one or more of procaine, tetracaine, obucaine and lidocaine.
8. The preparation method of the lubrication anesthesia antibacterial eye ointment is characterized by comprising the following steps of:
mixing the aqueous solution of glycosaminoglycan and the aqueous solution of quaternized chitosan, and centrifuging to obtain the lubricating anesthetic antibacterial eye ointment.
9. The preparation method of claim 8, wherein the mass concentration of the glycosaminoglycan in the aqueous solution of the glycosaminoglycan is 1% -5%;
the mass concentration of the quaternized chitosan in the water solution of the quaternized chitosan is 1% -5%.
10. The lubricating anesthetic antibacterial eye ointment according to any one of claims 1 to 7 or the lubricating anesthetic antibacterial eye ointment prepared by the preparation method according to claim 8 or 9, characterized in that the lubricating anesthetic antibacterial eye ointment is applied as a lubricating eye ointment for fundus screening.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310702479.2A CN116440069A (en) | 2023-06-14 | 2023-06-14 | Lubrication anesthesia antibacterial eye ointment and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310702479.2A CN116440069A (en) | 2023-06-14 | 2023-06-14 | Lubrication anesthesia antibacterial eye ointment and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116440069A true CN116440069A (en) | 2023-07-18 |
Family
ID=87122279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310702479.2A Pending CN116440069A (en) | 2023-06-14 | 2023-06-14 | Lubrication anesthesia antibacterial eye ointment and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116440069A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958251A (en) * | 2015-06-10 | 2015-10-07 | 杨甫进 | Preparation method of hyaluronic acid nanogel |
| WO2016170284A1 (en) * | 2015-04-23 | 2016-10-27 | Cytosial Biomedic | Homogeneous aqueous solution of injectable chitosan having a ph close to physiological ph |
| JP2017137307A (en) * | 2016-02-03 | 2017-08-10 | 学校法人慶應義塾 | Drug for improvement/treatment of sleep disorder and mood disorder of patients with dry eye |
| CN108904633A (en) * | 2018-10-19 | 2018-11-30 | 长沙浩然医疗科技有限公司 | A kind of eye ointment and preparation method thereof improving eyesight |
| WO2020228736A1 (en) * | 2019-05-14 | 2020-11-19 | 暨南大学 | Sustained-release microgel ointment having high drug loading capacity, preparation method therefor and application thereof |
-
2023
- 2023-06-14 CN CN202310702479.2A patent/CN116440069A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016170284A1 (en) * | 2015-04-23 | 2016-10-27 | Cytosial Biomedic | Homogeneous aqueous solution of injectable chitosan having a ph close to physiological ph |
| CN104958251A (en) * | 2015-06-10 | 2015-10-07 | 杨甫进 | Preparation method of hyaluronic acid nanogel |
| JP2017137307A (en) * | 2016-02-03 | 2017-08-10 | 学校法人慶應義塾 | Drug for improvement/treatment of sleep disorder and mood disorder of patients with dry eye |
| CN108904633A (en) * | 2018-10-19 | 2018-11-30 | 长沙浩然医疗科技有限公司 | A kind of eye ointment and preparation method thereof improving eyesight |
| WO2020228736A1 (en) * | 2019-05-14 | 2020-11-19 | 暨南大学 | Sustained-release microgel ointment having high drug loading capacity, preparation method therefor and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11878030B2 (en) | Ophthalmic formulations comprising cooperative complexes of low- and high-molecular-weight hyaluronic acid | |
| US20100222308A1 (en) | Ophthalmic, otic or nasal pharmaceutical composition and the use thereof | |
| CN105816476A (en) | Ophthalmic compositions containing mucoadhesive polysaccharides able to promote corneal re-epithelization | |
| CN105658203A (en) | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent | |
| Xu et al. | Preparation and characterization of ion-sensitive brimonidine tartrate in situ gel for ocular delivery | |
| CN116440069A (en) | Lubrication anesthesia antibacterial eye ointment and preparation method and application thereof | |
| CN105708844B (en) | A kind of tobramycin dexamethasone nanometer suspension eye drops and preparation method thereof | |
| CN101732238B (en) | Mitomycin c ophthalmic gel | |
| CN109136307B (en) | Method for preparing chitosan oligosaccharide by using helicase and application thereof | |
| CN1857506A (en) | Instant cordate houttuynia gel preparation for eye and its preparing method | |
| CN112891326B (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| CN109402219B (en) | Sterility inspection method of azithromycin eye drops | |
| CN106137954A (en) | Comprise eye drop with stable viscosity of polyhydric alcohol inorganic salt xanthan gum ternary system and preparation method thereof | |
| CN100508950C (en) | Method for preparation of cross-linking hyaluronic acid sodium jelly glue implanted in eyes | |
| CN112904590B (en) | Natamycin nanoparticle-loaded contact lens and preparation method thereof | |
| Budak et al. | Aqueous humor level of sCD44 in patients with degenerative myopia and primary open-angle glaucoma | |
| CN107296791A (en) | A kind of azithromycin micro emulsion eye drops | |
| CN104083323B (en) | Comprise the eye suspension of tobramycin and Betamethasone Valerate | |
| CN115300453B (en) | Ophthalmic thermosensitive gel containing chloramphenicol nanoparticles and preparation method thereof | |
| CN110947036B (en) | Lacrimal passage suppository and preparation method thereof | |
| CN117482038A (en) | Antibacterial hydrogel for treating bacterial keratitis through multi-mode strategy and preparation method and application thereof | |
| Mahesh et al. | Ion activated in situ gel system for ophthalmic delivery of Moxifloxacin hydrochloride | |
| CN111228214A (en) | Erythrocyte membrane-based hydrogel contact lens and preparation method and application thereof | |
| CN105999239A (en) | Lysozyme hydrochloride eye drops and preparation method and application thereof | |
| CN115337264A (en) | Improved and synergistic tobramycin eye drops and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230718 |
|
| RJ01 | Rejection of invention patent application after publication |